0001437749-21-027623.txt : 20211201
0001437749-21-027623.hdr.sgml : 20211201
20211201160552
ACCESSION NUMBER: 0001437749-21-027623
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211130
FILED AS OF DATE: 20211201
DATE AS OF CHANGE: 20211201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Echerd Margaret
CENTRAL INDEX KEY: 0001530193
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35285
FILM NUMBER: 211462973
MAIL ADDRESS:
STREET 1: 3585 MONROE STREET
CITY: SANTA CLARA
STATE: CA
ZIP: 95051
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxart, Inc.
CENTRAL INDEX KEY: 0000072444
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 591212264
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 HARBOR WAY, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 550-3500
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Aviragen Therapeutics, Inc.
DATE OF NAME CHANGE: 20160413
FORMER COMPANY:
FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20121113
FORMER COMPANY:
FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS
DATE OF NAME CHANGE: 20100719
4
1
rdgdoc.xml
FORM 4 ECHERD
X0306
4
2021-11-30
0000072444
Vaxart, Inc.
VXRT
0001530193
Echerd Margaret
C/O VAXART, INC.
170 HARBOR WAY, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
SVP, Principal Accntng Officer
Common Stock
2021-11-30
4
M
0
666
5.17
A
666
D
Common Stock
2021-11-30
4
M
0
2936
0.77
A
3602
D
Common Stock
2021-11-30
4
S
0
3602
8
D
0
D
Stock Option (right to buy)
5.17
2021-11-30
4
M
0
666
0
D
2028-05-24
Common stock
666
1667
D
Stock Option (right to buy)
0.77
2021-11-30
4
M
0
2936
0
D
2029-06-11
Common stock
2936
26416
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021.
The stock option vests over a four-year period, with 25% of the shares subject to the stock option vesting on the first anniversary of the vesting commencement date of April 9, 2018, and the remaining shares in 36 equal monthly installments thereafter.
The stock option vests over a four-year period, with 25% of the shares subject to the stock option vesting on the first anniversary of the vesting commencement date of May 10, 2019, and the remaining shares in 36 equal monthly installments thereafter.
/s/ Margaret Echerd
2021-12-01